Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CEST

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08:48aDJGLAXOSMITHKLINE : Glaxo Hones R&D Focus to 4 Diseases -- WSJ
07/26DJGLAXOSMITHKLINE : Glaxo Ditches Raft of R&D Projects to Focus on Best Prospects ..
07/26DJGLAXOSMITHKLINE : Correction to Glaxo Ditches Raft of R&D Projects Article
07/26DJGLAXOSMITHKLINE : Glaxo Ditches Raft of R&D Projects to Focus on Best Prospects ..
07/26 GLAXOSMITHKLINE : Glaxo reports 2Q loss
07/26 GLAXOSMITHKLINE : Director/PDMR Shareholding - Replacement
07/26DJGLAXOSMITHKLINE : Sharpens R&D, Axes 30 Research Programs
07/26 GLAXOSMITHKLINE : GSK delivers further progress in Q2 and sets out new prioritie..
07/25 GLAXOSMITHKLINE : Switching to a dolutegravir regimen from a boosted protease in..
07/25 GLAXOSMITHKLINE : ViiV announces positive results from DAWNING
More news
News from SeekingAlpha
02:32a GlaxoSmithKline's (GSK) CEO Emma Walmsley on Q2 2017 Results - Earnings Call ..
07/26 Glaxo Gets Out The Axe
07/26 Glaxo Q2 top line up 12%; loss/share 3.7p; cash flow down 18%; shares down 2%..
07/26 GlaxoSmithKline reports Q2 results
07/25 Gilead Puts Up The Good Fight Once Again
Financials ( GBP)
Sales 2017 30 080 M
EBIT 2017 8 310 M
Net income 2017 4 370 M
Debt 2017 13 968 M
Yield 2017 5,18%
P/E ratio 2017 17,34
P/E ratio 2018 15,21
EV / Sales 2017 2,99x
EV / Sales 2018 2,88x
Capitalization 76 014 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,8  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-1.06%99 860
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.69%220 651
ROCHE HOLDING LTD.4.08%220 599
PFIZER1.91%197 115
MERCK AND COMPANY4.98%170 565